Last reviewed · How we verify

NCT06777160

Predicting Bone Cement Implantation Syndrome Using Artificial Intelligence Methods

Recruiting now Last updated 15 January 2025
What this trial tests

trial testing Collecting data from patients who underwent arthroplasty and cement was used in Bone Cement Implantation Syndrome in 250 participants. Currently enrolling.

Timeline
8 September 2024
Primary endpoint
20 March 2025
15 April 2025

Quick facts

Lead sponsorAtaturk University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment250
Start date8 September 2024
Primary completion20 March 2025
Estimated completion15 April 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ataturk University

Who can join

18 and older, any sex, with Bone Cement Implantation Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to predict the development of bone cement syndrome, which may develop due to polymethylmethacrylate cement used to adhere the prosthesis to the bone in arthroplasty surgeries, which may cause intraoperative and postoperative mortality and morbidity, using artificial intelligence methods and to provide a sustainable life comfort to patients in the postoperative period with the standardization predicted in the long term.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ataturk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06777160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing